Comparative Pharmacology
Head-to-head clinical analysis: EXEMESTANE versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXEMESTANE versus TESLAC.
EXEMESTANE vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible steroidal aromatase inhibitor; binds to the substrate-binding site of aromatase, causing permanent inactivation of the enzyme. Reduces estrogen synthesis by inhibiting conversion of androgens to estrogens.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
25 mg orally once daily after a meal.
250 mg intramuscularly three times per week
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing. Steady state is achieved after 7 days.
Clinical Note
moderateExemestane + Digoxin
"Exemestane may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateExemestane + Digitoxin
"Exemestane may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateExemestane + Deslanoside
"Exemestane may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateExemestane + Acetyldigitoxin
"Exemestane may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Primarily hepatic metabolism (CYP3A4 and aldoketoreductases) with fecal excretion of metabolites (approximately 80-90%) and renal excretion of unchanged drug and metabolites (approximately 10-20%).
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category D/X
Category C
Aromatase Inhibitor
Aromatase Inhibitor